CEACAM5 and cancer: The combination of a more extended tumour marker profile, including the addition of carcinoembryonic antigen (CEA) and/ or carbohydrate antigen (CA 19-9) to CA 125, is useful mainly for differentiating between metastatic tumours from the gastrointestinal tract or pancreas and primary ovarian malignancy (Bozkurt et al., 2013; Kelly et al., 2010; Sagi-Dain et al., 2015a, 2015b).